Shares of the Chinese drug developer-- $KINTOR PHARMA-B(09939.HK)$ increased 11.50% to 28.60 as at 10:50 am. $KINTOR PHARMA-B(09939.HK)$ surged over 170% in the last five trading days.
Kintor Pharma's Proxalutamide demonstrated a reduction in hospitalization/mortality for patients with mild to moderate COVID-19 in Phase III MRCT study.
●Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p <0.02).
● Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors.
● Proxalutamide demonstrates significant reduction in COVID-19 viral load and improved coronavirus-related symptoms.
● The Phase III multi-regional clinical trial (MRCT) enrolled 99% of patients in multiple centers accross the United States.